Filing Flows › Xilio Therapeutics (XLO) › Q2 2026 › vs Q1 2026
Xilio Therapeutics (XLO) Q2 2026 vs Q1 2026 (quarter over quarter)
Xilio Therapeutics's revenue rose $6.0M (+48%) from $12.6M in Q1 2026 to $18.7M in Q2 2026.
Xilio Therapeutics, Q2 2026: revenue $18.7M (+131% year over year), operating margin -18.7%, net loss $6.4M, operating cash flow −$18.8M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $18.7M | $12.6M | $6.0M | +48% |
| Net loss | $6.4M | $9.5M | −$3.2M | -33% |
| Costs & expenses | $25.1M | $26.8M | −$1.7M | -6% |
| Operating costs | $22.2M | $26.8M | −$4.6M | -17% |
| Interest & other, net | $2.9M | −$4.6M | $7.5M | — |
| Research & development | $14.6M | $19.8M | −$5.3M | -27% |
| General & admin | $7.6M | $6.9M | $696K | +10% |
| Operating cash sources | $20.7M | $24.9M | −$4.2M | -17% |
| Depreciation & amortization | $331K | $344K | −$13K | -4% |
| Share-based compensation | $1.6M | $2.2M | −$613K | -28% |
| Cash used in operations | $18.8M | $22.3M | −$3.6M | -16% |
| Net loss absorbed | $6.4M | $9.5M | −$3.2M | -33% |
| Working capital & other | $14.3M | $15.4M | −$1.1M | -7% |
Questions
How much did Xilio Therapeutics's revenue grow quarter over quarter in Q2 2026?
Xilio Therapeutics's revenue rose $6.0M (+48%) from $12.6M in Q1 2026 to $18.7M in Q2 2026.